Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver.
about
MicroRNA-regulated viral vectors for gene therapyCurrent prospects and challenges for epilepsy gene therapySystemic injection of AAV9 carrying a periostin promoter targets gene expression to a myofibroblast-like lineage in mouse hearts after reperfused myocardial infarction.Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in δ-Sarcoglycan-deficient hamsters.Endothelial transcription factor KLF2 negatively regulates liver regeneration via induction of activin AEngineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer.Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10A selective microRNA-based strategy inhibits restenosis while preserving endothelial function.Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.Adipose tissue insulin receptor knockdown via a new primate-derived hybrid recombinant AAV serotype.Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.Targeting adipose tissue via systemic gene therapyIntramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression.Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors.AAV ancestral reconstruction library enables selection of broadly infectious viral variants.Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.Novel Strategy to Control Transgene Expression Mediated by a Sendai Virus-Based Vector Using a Nonstructural C Protein and Endogenous MicroRNAs.Persistence, localization, and external control of transgene expression after single injection of adeno-associated virus into injured joints.Application of mutated miR-206 target sites enables skeletal muscle-specific silencing of transgene expression of cardiotropic AAV9 vectors.Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector.Enhancing the utility of adeno-associated virus gene transfer through inducible tissue-specific expression.Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of α-dystroglycan and improves muscle functionsEvaluation of miR-122-regulated suicide gene therapy for hepatocellular carcinoma in an orthotopic mouse model.K137R mutation on adeno-associated viral capsids had minimal effect on enhancing gene delivery in vivo.MicroRNA silencing and the development of novel therapies for liver disease.Adeno-associated virus vectors and neurological gene therapy.CRISPR genome engineering and viral gene delivery: a case of mutual attraction.microRNA and Ovarian Cancer.Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.In vivo adeno-associated viral vector-mediated genetic engineering of white and brown adipose tissue in adult mice.MicroRNA-150-regulated vectors allow lymphocyte-sparing transgene expression in hematopoietic gene therapy.Development of hybrid baculovirus vectors for artificial MicroRNA delivery and prolonged gene suppression.Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler-Najjar Syndrome Type I.Next-generation AAV vectors for clinical use: an ever-accelerating race.Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver.Systemic and Persistent Muscle Gene Expression in Rhesus Monkeys with a Liver De-Targeted Adeno-Associated Virus Vector.Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery.Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart.Targeting transgene to the heart and liver with AAV9 by different promoters.Engineered AAV vectors for improved central nervous system gene delivery.
P2860
Q26745822-6638BD6A-B302-4700-AFBD-9080CE68D211Q27002627-E0B4AADD-A27A-47A7-8652-29B7A2F0D0E0Q30277247-6F961DEA-D9E8-4238-93D3-6BAF329D7BE3Q30512833-E723989C-AF8B-4D7D-9EA1-733960AE638BQ33569270-4CF9F0BD-E805-4BE3-BD76-55E0815E0A2FQ33833473-FF63CFBB-E095-49DB-B509-7671A4517C70Q33870720-5E63B781-430E-452B-BB30-48604226A0C0Q34129012-A499BCA1-A01D-46E3-B6F5-C8AD866CAB8FQ34370111-704ED2FC-B792-49D6-8288-26AB78DA1A42Q34472188-B2EABC4C-A0F9-4340-A75C-EA66AC430C28Q34566454-D8D21EBB-5E44-4235-AD86-FE36D9763F0DQ35125440-A46623A8-45C2-4441-962D-CC9E874AFD2AQ35418068-8253DC9E-91AC-4DD1-947D-A36B13E0A7EAQ35649591-9896A5AD-8294-47A5-A55E-5896109C2122Q35695082-34B0AA1A-C44A-41B8-80AE-22DEA922CD3EQ35853990-34D6EFB0-E22C-475B-91C5-24D9AFBFB15BQ36169226-16BEBFE6-1121-49C0-95E1-0B2BBCD1D8FEQ36780068-0FB731DD-F087-499F-AF46-10071837F90DQ36883822-7F45BCD0-3E0F-4633-B768-AB1622D6E782Q37043485-F5143483-842A-4F94-AB04-27292338E98BQ37122371-7B460761-A339-4C2A-BC76-CFB3E347DCE2Q37254859-6843D565-F437-49EB-8B70-221461A91E9BQ37413629-6DC78EEF-FCFC-4663-A281-E13F894020D2Q37524906-1469046C-482B-4D25-B3BC-984666D0A7F3Q38002726-CE2E603B-9D61-4F82-BB84-A32C0304C7B6Q38190041-62438696-07CB-4A29-881B-6A080AD48DF5Q38348602-42B1E589-8AAA-43F7-99E7-9041E4507622Q38667018-94AB4D43-15C6-4512-B275-7926883524D4Q38856794-A0B0BA24-EB66-4E17-A41D-08C141461BF6Q39348746-3E4E1C39-168F-45D6-A18C-A83B020B0B49Q39462857-C303C506-5B09-4994-B398-781A4D0E3DF1Q39512175-BF844784-3BA0-4165-838C-5CFB8D0207C5Q40084021-C69D72CB-0D4C-475A-AC5F-0DB876D74453Q40100060-6C01EB8B-D029-40F0-B238-8CBA5F91368CQ40124877-7EE1CC0E-FC53-4E61-B2FA-B6F448EBF56EQ40363166-8D93B377-F48A-4010-9C2C-D2B5AD0D5820Q40610977-BD0513AF-B0C7-4F40-BC88-38640A9C2F97Q40619677-96B34123-8BDD-4FDB-943C-029AA7428F1BQ40738027-B11E985E-3565-4406-91AC-1CE41EBFF312Q41815391-FB78457B-3FA7-46C6-8A7B-8EFD0E6B0609
P2860
Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Liver-specific microRNA-122 ta ...... sgene expression in the liver.
@en
type
label
Liver-specific microRNA-122 ta ...... sgene expression in the liver.
@en
prefLabel
Liver-specific microRNA-122 ta ...... sgene expression in the liver.
@en
P2093
P2860
P356
P1433
P1476
Liver-specific microRNA-122 ta ...... sgene expression in the liver.
@en
P2093
P2860
P2888
P304
P356
10.1038/GT.2010.157
P577
2010-12-09T00:00:00Z